D. E. Shaw & Co., Inc. Summit Therapeutics Inc. Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 130,627 shares of SMMT stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,627

Previous 137,445 4.96%

Holding current value

$2.38 Million

Previous $2.92 Million 7.42%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$17.61 - $30.02 $120,064 - $204,676	-6,818 Reduced 4.96%	130,627 $2.71 Million
Q2 2025 Aug 14, 2025	BUY	$16.64 - $36.7 $1.79 Million - $3.95 Million	107,666 Added 361.55%	137,445 $2.92 Million
Q1 2025 May 15, 2025	SELL	$16.65 - $23.76 $103,929 - $148,309	-6,242 Reduced 17.33%	29,779 $574,000
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $6.41 Million - $8.59 Million	-366,146 Reduced 91.04%	36,021 $642,000
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $2.57 Million - $11.9 Million	372,467 Added 1254.1%	402,167 $8.81 Million

Q2 2024 Aug 14, 2024	BUY	$2.39 - $10.92 $70,983 - $324,324	29,700 New	29,700 $231,000
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $30,292 - $52,253	-15,146 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $19,609 - $45,142	-8,004 Reduced 34.57%	15,146 $41,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $8.27 $62,732 - $107,410	12,988 Added 127.81%	23,150 $116,000
Q2 2021 Aug 16, 2021	BUY	$5.15 - $8.46 $52,334 - $85,970	10,162 New	10,162 $76,000

Others Institutions Holding SMMT

# of Institutions

267

Shares Held

94.2M

Call Options Held

4.72M

Put Options Held

4.03M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.67B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account